Picture a pinned video on a GLP-1 seller's social feed. Someone asks if the drugs are legit, and the answer, with one word bleeped, is that they're super legit. The FDA was not persuaded. You're listening to GLP-1 Daily, and today is Wednesday, November 4. We open with an FDA warning letter about how one company sold compounded semaglutide and tirzepatide online. Then New Zealand's medicines-funding agency explains why Wegovy for weight loss still isn't publicly paid for there. And obesity doctors react to a study suggesting more than a million Americans may be taking these drugs off-label.
From the FDA's Center for Drug Evaluation and Research, in a warning letter to RonanRx dated Friday, October 30:
The following claims concerning compounded semaglutide and tirzepatide products appear on your website: “Well-Studied Compounded Medications,” accompanied by the description, “Compounded medications with substantial human clinical evidence—randomized trials, mechanistic studies, and decades of use—though the specific compounded preparation may not itself be FDA-approved.” “FDA-Approved Compounded Medications,” accompanied by the description, “Compounded medications whose active ingredient has at least one FDA-approved branded form for the indication described.”
RonanRx is based in Elgin, Texas. The agency says it reviewed the company's website and its account on X in September, and found the marketing for its compounded semaglutide and tirzepatide false or misleading. Under federal law, that makes the products misbranded. FDA-approved compounded medications. That phrase is doing a lot of work, and the letter's answer is short: compounded drug products are not FDA-approved. There's a second problem the FDA flags, and I think it's the more important one for patients. Product photos on the site and on X showed RonanRx on the label, which the agency says suggests RonanRx compounds those drugs, when in fact it does not. So the name on the vial in the picture isn't the outfit that made what's in it.Some boundaries on what this letter is. It's about marketing claims and labeling, found through a review of the website and social media. It isn't a lab finding about what's in the product. The FDA says its list isn't all-inclusive, and it warns that failing to fix the violations could lead to legal action without further notice, including seizure and injunction. And one letter about one seller is not a verdict on compounding as a whole. Properly licensed pharmacies are part of how a lot of people afford these drugs. The problem here is the marketing, and marketing like this makes it harder to tell the careful operators from the careless ones. If you get a compounded GLP-1, ask your prescriber or the dispensing pharmacy which pharmacy actually made it and whether it's registered with the FDA or licensed by the state. Don't switch products or sources on your own.
From Pharmac, New Zealand's government medicines-funding agency, in an update posted Tuesday, November 3:
The Obesity Treatment Advisory Group recommended that Pharmac fund semaglutide (Wegovy) for chronic weight management in people with a high Body Mass Index (BMI) and associated comorbidities with a high priority.
That advice dates to a December 2025 meeting. New Zealand's regulator, Medsafe, has approved both Wegovy and Mounjaro for weight loss. But approval and public funding are separate decisions there, and Pharmac makes the second one. As of this week, neither drug is funded for weight loss. Here's where Wegovy stands. Pharmac has assessed the application and put it on what it calls its Options for Investment List. Separately, in October its cardiovascular advisory committee looked at two applications to fund Wegovy for people with heart disease and a high BMI, and also signaled high priority. And on timing, Pharmac's own words are blunt: it cannot say when, or if, any medicine will be funded. Two expert panels say high priority, and the answer is still a list. Calling that a backlog is generous. Choosing what to fund first is exactly what that budget process exists to do. On Mounjaro, Pharmac says it hasn't received an application to fund it for weight loss at all. There is one for type 2 diabetes that isn't well controlled, and that's being assessed now. For now, New Zealanders prescribed either drug pay for it themselves, and Pharmac says it doesn't control that price. Two older GLP-1s, Trulicity and Victoza, are funded for type 2 diabetes for people who meet the criteria. For listeners in the U.S., the pattern should sound familiar from yesterday's Ohio Medicaid story. With a diabetes diagnosis there's often a funded path. Without one, you're usually paying out of pocket. If that describes you, ask your prescriber whether any diagnosis you actually have changes what your plan will cover.
Virginia Anderson, writing for Medscape:
The issue is complicated because GLP-1s are available online without a prescription — and without the benefit of medical oversight while taking them. And PCPs are increasingly being asked about the drugs, originally approved to treat diabetes and later, obesity and overweight with certain comorbidities.
The piece ran Tuesday. It starts from a study by New York University researchers, published this month in the journal Obesity, which suggested more than a million people may be taking GLP-1s off-label. Medscape then asked obesity specialists what primary care doctors should do about it. And the specialists didn't all buy the framing. Catherine Varney, obesity medicine director at UVA Health, disagreed with the suggestion that primary care doctors are prescribing these drugs inappropriately. Dan Azagury, who runs Stanford's weight management program, agreed with her. In his view, the danger lies with low-quality, low-resource providers. Varney also questioned the study's methods. She says it left out people with a BMI of 25 or 26, so it doesn't represent people with overweight who also have a related health condition. That's a critique from one clinician, not a published rebuttal. And for disclosure, Medscape notes she has been a speaker and advisory board member for Eli Lilly. The other experts reported no relevant disclosures. So the risk isn't the family doctor who checks your labs. It's the website that never asks you to step on a scale, which is how Amy Sheer at University of Florida Health put it. The experts were united on one point. People with anorexia or other disordered eating should never be prescribed a GLP-1. And anyone prescribed one should get counseling on side effects, nutrition with enough protein and fiber, and exercise to protect against muscle loss. If you're getting a GLP-1 through an online service, bring the details to a clinician who knows your history. That includes your dose, who's monitoring you, and how long you plan to stay on it.
A quick request before we go. If today helped you read a warning letter or a funding notice more clearly, a rating or a few words of review in your podcast app helps other patients find GLP-1 Daily.
Today we had a seller calling compounded drugs FDA-approved, a country that keeps Wegovy on a list but not on its budget, and doctors arguing over who's actually prescribing off-label. This is a news briefing. Your treatment decisions belong with your own prescriber. GLP-1 Daily is made by Lantern Podcasts. We'll see you tomorrow, Thursday, November 5.